Loading data for QNRX — first visit, this takes a few seconds.
Quoin Pharmaceuticals, Ltd. (QNRX): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$1.90 | -$0.13 | +69.70% |
Métricas
- Precio de compra
- 7.75
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -18.7M
- 1.73
- -5.67
- n/a
- -2.12
- P/B (TTM)
- 0.77
- P/S (TTM)
- n/a
- Fecha de resultados
- n/a
- Precio de venta
- 7.65
- Volumen
- 65,622
- Volumen medio (20D)
- 780,565
- Abierto
- 6.87
- Anterior Cerrar
- 6.90
- Rango del día
- 6.66 - 6.87
- Rango de 52 semanas
- 3.25 - 41.80
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Quoin Pharmaceuticals, Ltd.
Ver perfil →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Industria Biotechnology
Sector Healthcare
IPO Fecha Aug 1, 2016
Empleados 4
Bolsa de Valores NasdaqCM
Símbolo bursátil QNRX
Sitio web https://quoinpharma.com